Rights and permissions
About this article
Cite this article
Docetaxel superior choice over mitoxantrone in prostate cancer. Inpharma Wkly. 1459, 9 (2004). https://doi.org/10.2165/00128413-200414590-00022
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200414590-00022